Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia

Abstract EN

Aim.

To examine the potential value of previously identified biomarkers using proteomics in early screening for preeclampsia (PE).

Methods.

24 blood samples from women who subsequently developed PE and 48 from uncomplicated pregnancies were obtained at 11–13 weeks and analysed after delivery.

Cystatin-C, sVCAM-1, and Pappalysin-1 were quantified by ELISA.

Maternal characteristics and medical history were recorded.

Results.

Median values of Cystatin-C, sVCAM-1, and Pappalysin-1 in the PE group as compared to controls were 909.1 gEq/mL versus 480.0 gEq/mL, P = .

000 , 832.0 gEq/mL versus 738.8 gEq/mL, P = .

024 , and 234.4 gEq/mL versus 74.9 gEq/mL, P = .

064 , respectively.

Areas under the receiver-operating characteristic curves (AUC, standard error (SE)) for predicting PE were Cystatin-C: 0.90 (SE 0.04), VCAM-1: 0.66 (SE 0.074), and Pappalysin-1: 0.63 (SE 0.083).

To discriminate between cases at risk for PE and normal controls, cut-off values of 546.8 gEq/mL for Cystatin-C, 1059.5 gEq/mL for sVCAM-1, and 220.8 gEq/mL for Pappalysin-1 were chosen, providing sensitivity of 91%, 41%, and 54% and specificity of 85%, 100%, and 95%, respectively.

Conclusions.

sVCAM-1 and Pappalysin-1 do not improve early screening for PE.

Cystatin-C, however, seems to be associated with subsequent PE development, but larger studies are necessary to validate these findings.